title: [A case report: patient with advanced ovarial tumour and supporting care].
abstract: BACKGROUND
  The primary aim of palliative treatment is to improve the quality of life, followed by prolongation of overall survival. The effective regimens are usually complicated by increased side effects, particularly hematologic. Under these conditions, useful treatment is difficult and less effective.
  
  
  METHODS
  We present the case of a patient with cancer of the abdominal and pelvic cavity (the origin was likely an ovary). The patient was treated with intensive chemotherapy (15 cycles of carboplatin and paclitaxel) and supportive care (30 doses of epoetin alpha and 2 doses of 48MIU G-CSF for neutropenia G4).
  
  
  CONCLUSIONS
  A good quality of life and long-term persistent complete remission (6 months) was achieved, no transfusion, no hospitalization. Overall survival was 61 months.
authors.affiliation: Hematologicka a onkologicka klinika, FN Brno. dagmar.brancikova@fnbrno.cz
authors.forename: D
authors.initials: D
authors.lastname: Brančíková
authors.forename: L
authors.initials: L
authors.lastname: Ostřížková
authors.forename: M
authors.initials: M
authors.lastname: Protivánková
authors.forename: O
authors.initials: O
authors.lastname: Bednařík
authors.forename: Z
authors.initials: Z
authors.lastname: Mechl
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D000068817:Epoetin Alfa